Fundraising Fox
/Companies
Sign in

Progentos Therapeutics

Watertown, US · Founded 2023 · Delaware corporation · 6 known investors

Find your way into Progentos Therapeutics

Sign up to see every warm intro you have to Progentos Therapeutics

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Progentos Therapeutics team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Progentos develops small-molecule therapeutics to stimulate myelin regeneration in multiple sclerosis patients by activating oligodendrocyte progenitor cells. The company targets the significant unmet need for remyelinating treatments that could repair damage caused by MS and potentially restore lost function.

BiotechDeep TechMedical Devices

Founders & leadership

DHDmitrij Hristodorov
Dmitrij HristodorovBoard MemberGeneral Partner at Forbion
CL
Christopher LooseNamed on SEC filing
SM
Sanjay MagaviNamed on SEC filing
MTMarc-Olivier Turgeon
Marc-Olivier TurgeonBoard Member2024–2026Senior Associate at Forbion

Board

ARAleks Radovic-Moreno
Aleks Radovic-MorenoBoard MemberPartner at Longwood Fund
DJ
Dan JanneyBoard directorManaging Director at Alta Partners
CBCassidy Blundell
Cassidy BlundellBoard directorPartner at Mission Biocapital

Investors · 6

Dolby Family Ventureslisted by Dolby Family VenturesSan Francisco

How we know: Dolby Family Ventures's portfolio page · funding news · biopharmadive.com · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us

Longwood Fundlisted by Longwood FundBoston

How we know: Longwood Fund's portfolio page · a partner's Signal profile · funding news · biopharmadive.com · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us

Mission Biocapitallisted by Mission BiocapitalSan Francisco · $500K

How we know: Mission Biocapital's portfolio page · funding news · biopharmadive.com · the VCSheet dataset · Not right? Tell us

Service Provider Capitallisted by Service Provider CapitalVail

How we know: the VCSheet dataset · Not right? Tell us

ForbionreportedNaarden

How we know: a partner's Signal profile · biopharmadive.com · open dataset · 5k.vc investor directory · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$68.6M disclosed across 1 round · 2024

▶$68.6MraisedMay 2024 · 39 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Aleks Radovic-MorenoDirector
  • Dmitrij HristodorovDirector
  • Dan JanneyDirector
  • Christopher LooseExecutive Officer, Director
  • Cassidy BlundellDirector
  • Sanjay MagaviExecutive Officer
  • Marc-Olivier TurgeonDirector
Offering amount
$68.6M
Amount sold
$68.6M
First sale
May 2024
Incorporated
Corporation, Delaware, 2023
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 5

Regeneron NASDAQ: REGN www.regeneron.comRegeneron is a biotechnology company that develops medicines ranging from biologics to genetic medicines to treat serious diseases across areas such as metabolic disease, ophthalmology, and rare disease. The company focuses on research and development driven by human biology, with a clinical trial pipeline addressing conditions like generalized myasthenia gravis.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
PrecigenPrecigen is a biopharmaceutical company developing gene and cell therapies, including PAPZIMEOS (zopapogene imadenovec-drba), an FDA-approved immunotherapy for adults with recurrent respiratory papillomatosis. The company focuses on immuno-oncology and immunotherapy treatments delivered via subcutaneous injection.
PepGenPepGen is a clinical-stage biotech company developing oligonucleotide therapies for neuromuscular and neurological diseases using its Enhanced Delivery Oligonucleotide (EDO) platform to improve tissue penetration and uptake in muscle tissues.
ForbionA venture capital firm investing in biotech companies across all stages of pharmaceutical development, and in sustainable solutions across food, agriculture, materials, and environmental technologies through its BioEconomy strategy.

Companies working in the same space as Progentos Therapeutics.

Frequently asked questions

What does Progentos Therapeutics do?
Progentos develops small-molecule therapeutics to stimulate myelin regeneration in multiple sclerosis patients by activating oligodendrocyte progenitor cells. The company targets the significant unmet need for remyelinating treatments that could repair damage caused by MS and potentially restore lost function.
Who are Progentos Therapeutics's investors?
Progentos Therapeutics's investors include Alta Partners, Dolby Family Ventures, Longwood Fund, Mission Biocapital, Service Provider Capital, Forbion.
How much funding has Progentos Therapeutics raised?
Progentos Therapeutics has disclosed $68.6M raised across 1 round.
Where is Progentos Therapeutics headquartered?
Progentos Therapeutics is headquartered in Watertown, US.